Diagnostics,
Journal Year:
2024,
Volume and Issue:
14(21), P. 2356 - 2356
Published: Oct. 22, 2024
Lung
cancer,
also
known
as
lung
carcinoma,
has
a
high
mortality
rate;
however,
an
early
prediction
helps
to
reduce
the
risk.
In
current
literature,
various
approaches
have
been
developed
for
of
carcinoma
(at
stage),
but
these
still
issues,
such
low
accuracy,
noise,
contrast,
poor
recognition
rates,
and
false-positive
rate,
etc.
Thus,
in
this
research
effort,
we
proposed
advanced
algorithm
combined
two
different
types
deep
neural
networks
make
it
easier
spot
melanoma
phases.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(4), P. 3061 - 3061
Published: Feb. 4, 2023
Exosome,
a
subpopulation
of
extracellular
vesicles,
plays
diverse
roles
in
various
biological
processes.
As
one
the
most
abundant
components
exosomes,
exosomal
proteins
have
been
revealed
to
participate
development
many
diseases,
such
as
carcinoma,
sarcoma,
melanoma,
neurological
disorders,
immune
responses,
cardiovascular
and
infection.
Thus,
understanding
functions
mechanisms
potentially
assists
clinical
diagnosis
targeted
delivery
therapies.
However,
current
knowledge
about
function
application
is
still
limited.
In
this
review,
we
summarize
classification
proteins,
exosome
biogenesis
disease
development,
well
applications.
Journal of Pharmaceutical Analysis,
Journal Year:
2023,
Volume and Issue:
13(12), P. 1429 - 1451
Published: Aug. 24, 2023
With
the
continuous
discovery
and
research
of
predictive
cancer-related
biomarkers,
liquid
biopsy
shows
great
potential
in
cancer
diagnosis.
Surface-enhanced
Raman
scattering
(SERS)
microfluidic
technology
have
received
much
attention
among
various
biomarker
detection
methods.
The
former
has
ultrahigh
sensitivity
can
provide
a
unique
fingerprint.
In
contrast,
latter
characteristics
miniaturization
integration,
which
realize
accurate
control
samples
high-throughput
through
design.
Both
for
point-of-care
testing
(POCT),
their
combination
(lab-on-a-chip
SERS
(LoC-SERS))
good
compatibility.
this
paper,
basic
situation
circulating
proteins,
tumor
cells,
exosomes,
DNA
(ctDNA),
microRNA
(miRNA)
diagnosis
cancers
is
reviewed,
these
biomarkers
by
LoC-SERS
platform
recent
years
described
detail.
At
same
time,
challenges
future
development
are
discussed
at
end
review.
Summarizing
current
expected
to
reference
scholars
engaged
related
work
interested
field.
Lung Cancer,
Journal Year:
2023,
Volume and Issue:
178, P. 28 - 36
Published: Feb. 1, 2023
Pathologic
subtyping
of
tissue
biopsies
is
the
gold
standard
for
diagnosis
lung
cancer
(LC),
which
could
be
complicated
in
cases
e.g.
inconclusive
or
unreachable
tumors.
The
LC
supported
a
minimally
invasive
manner
using
protein
tumor
markers
(TMs)
and
circulating
DNA
(ctDNA)
measured
liquid
(LBx).
This
study
evaluates
performance
LBx-based
decision-support
algorithms
into
small-
non-small-cell
(SCLC
NSCLC)
aiming
to
directly
impact
clinical
practice.In
this
multicenter
prospective
(NL9146),
eight
TMs
(CA125,
CA15.3,
CEA,
CYFRA
21-1,
HE4,
NSE,
proGRP
SCCA)
ctDNA
mutations
EGFR,
KRAS
BRAF
were
analyzed
blood
1096
patients
suspected
LC.
individual
combined
identify
LC,
NSCLC
SCLC
was
established
by
evaluating
logistic
regression
models
at
pre-specified
positive
predictive
values
(PPV)
≥95%
≥98%.
most
informative
included
multi-parametric
selected
recursive
feature
elimination.Single
with
46%,
25%
40%
sensitivity,
respectively,
PPVs.
Multi-parametric
combining
significantly
improved
sensitivities
65%,
67%
50%,
respectively.In
allowed
identification
about
two-thirds
all
half
patients.
These
therefore
show
value
may
support
diagnostics,
especially
whom
pathologic
impossible
incomplete.
Diagnostics,
Journal Year:
2022,
Volume and Issue:
12(12), P. 2985 - 2985
Published: Nov. 29, 2022
Lung
cancer
is
the
second
most
commonly
diagnosed
in
world.
In
terms
of
diagnosis
lung
cancer,
combination
carcinoembryonic
antigen
(CEA)
and
125
(CA125)
detection
had
higher
sensitivity,
specificity,
diagnostic
odds
ratios
than
CEA
alone.
Most
individuals
with
elevated
serum
CA125
levels
that
was
either
stage
3
or
4.
Serum
were
similarly
patients
who
also
pleural
effusions
ascites.
Furthermore,
there
strong
evidence
human
produces
vitro,
which
suggests
other
clinical
illnesses
outside
ovarian
could
be
responsible
for
rise
CA125.
MUC16
a
natural
killer
cell
inhibitor.
As
screening
test
prognosis
early
stages,
has
been
widely
used
as
marker
three
different
settings.
mRNA
are
increased
regardless
gender.
well,
expression
mutated
enhances
cells
proliferation
growth.
Additionally,
level
thought
to
key
indicator
metastasis
liver.
Further,
useful
biomarker
types
diagnoses
like
ovarian,
breast,
pancreatic
cancers.
One
important
limitations
first
step
such
technique
up
20%
tumors
lack
expression.
Each
10
possible
markers
expressed
29–100%
minimal
no
Therefore,
controversy
regarding
types.
this
state,
preclinical
studies
warranted
elucidate
benefit
cancer.
Aging and Disease,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 1, 2024
Although
significant
progress
has
been
made
in
early
lung
cancer
screening
over
the
past
decade,
it
remains
one
of
most
prevalent
and
deadliest
forms
worldwide.
Exosomal
proteomics
emerged
as
a
transformative
field
research,
with
potential
to
redefine
diagnostics,
prognostic
assessments,
therapeutic
strategies
through
lens
precision
medicine.
This
review
discusses
recent
advances
exosome-related
proteomic
glycoproteomic
technologies,
highlighting
their
revolutionise
treatment
by
addressing
issues
heterogeneity,
integrating
multiomics
data,
utilising
advanced
analytical
methods.
While
these
technologies
show
promise,
there
are
obstacles
overcome
before
they
can
be
widely
implemented,
such
need
for
standardization,
gaps
clinical
application,
importance
dynamic
monitoring.
Future
directions
should
aim
challenges
fully
utilize
exosomal
cancer.
promises
new
era
personalized
medicine
that
leverages
molecular
complexity
exosomes
groundbreaking
advancements
detection,
prognosis,
treatment.
Nanoscale,
Journal Year:
2024,
Volume and Issue:
16(27), P. 12750 - 12792
Published: Jan. 1, 2024
Electrochemical
bio-sensing
is
a
potent
and
efficient
method
for
converting
various
biological
recognition
events
into
voltage,
current,
impedance
electrical
signals.
Biochemical
sensors
are
now
common
part
of
medical
applications,
such
as
detecting
blood
glucose
levels,
food
pathogens,
specific
cancers.
As
an
exciting
feature,
bio-affinity
couples,
proteins
with
aptamers,
ligands,
paired
nucleotides,
antibodies
antigens,
commonly
used
bio-sensitive
elements
in
electrochemical
biosensors.
Biotin-avidin
interactions
have
been
utilized
purposes
recent
years,
targeting
drugs,
diagnosing
clinically,
labeling
immunologically,
biotechnology,
biomedical
engineering,
separating
or
purifying
biomolecular
compounds.
The
interaction
between
biotin
avidin
widely
regarded
one
the
most
robust
reliable
noncovalent
due
to
its
high
bi-affinity
ability
remain
selective
accurate
under
reaction
conditions
bio-molecular
attachments.
More
recently,
there
numerous
attempts
develop
sense
circulating
cancer
cells
measurement
intracellular
levels
protein
thiols,
formaldehyde,
vitamin-targeted
polymers,
huwentoxin-I,
anti-human
antibodies,
variety
tumor
markers
(including
alpha-fetoprotein,
epidermal
growth
factor
receptor,
prostate-specific
Ag,
carcinoembryonic
antigen
125,
15-3,
etc.).
Still,
non-specific
binding
endogenous
biotin-binding
present
samples
can
result
false-positive
signals
hinder
detection
biomarkers.
This
review
summarizes
categories
biotin-functional
nanoparticles
designed
detect
biomarkers
highlights
some
challenges
using
them
diagnostic
tools.
